Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract
development and manufacturing organization (CDMO) dedicated to
solving complex formulation and manufacturing challenges primarily
in small molecule therapeutic development, today reported financial
results for the fourth quarter and year ended December 31, 2021.
“At this time last year, I announced a new
strategic vision for the company comprised of four areas of focus
for 2021 including: (1) expansion and diversification of Recro’s
customer base; (2) strengthening of our balance sheet position in
order to better support both organic and inorganic growth; (3)
augmentation of our leadership as well as optimizing our
operational organization and finally, (4) continuing to upgrade and
expand our facilities and capabilities to support growing customer
demand. I am very pleased to report that we made great progress
with each of these goals during 2021,” stated David Enloe,
president and chief executive officer of Recro.
“While we advanced each of these goals in the
first half of the year, our acquisition of IriSys, LLC last August
significantly contributed to our achievements in 2021. During the
year, our customer base more than tripled and is now more
diversified than at any time in the past. Organic new business grew
by 63% in 2021, and that growth climbs to 147% when including the
new business from the IriSys acquisition. Our financial position
significantly improved during 2021 due to an increase in revenue
and cash from operations, the successful de-levering of $25 million
of debt from our balance sheet, and raising gross proceeds of
approximately $34.5 million through an underwritten public offering
in May of last year. As a result of the IriSys acquisition, our
leadership, in-house expertise, capabilities and facilities were
all significantly enhanced. Finally, our operations have been
substantially optimized by re-structuring cost centers as global
functions across the organization.
“I am exceedingly proud of the company’s
performance in 2021, as we delivered on each of our stated goals
for the year. Looking ahead, the company will focus on a number of
new objectives that we believe will further elevate Recro. This
strategy includes executing segment-specific sales and marketing
strategies; building stronger visibility and an updated identity
for the organization; enhancing both our customers’ and our
employees’ experience working with and for the company,
respectively; and, continuing to achieve growth and strengthen our
financial position. We believe that the achievements of 2021
clearly demonstrate our ambition and ability to execute. Looking
ahead, we plan to leverage our expanded expertise, our enhanced
service offerings, our dedicated team, and our improved financial
position to elevate our company to fulfilling our vision of
becoming a premier, trusted growth-focused CDMO.”
Fourth Quarter 2021 and Other Recent
Developments
Strengthened leadership and
organizational improvements:
- The company recently appointed Eduardo Uribe as the company’s
head of quality for Recro San Diego. Mr. Uribe has more than 30
years of experience developing, implementing and managing quality
systems within the biotechnology and pharmaceutical industry,
including more than a decade in senior leadership positions
overseeing quality and compliance at a number of leading CDMOs. In
his new role with Recro, he will be responsible for strategic
planning and management of all quality and compliance initiatives
for the company’s San Diego operations.
New business growth:
- New manufacturing
customers. Among its new business awarded during the
fourth quarter of 2021, Recro was awarded a new formulation
development and cGMP manufacturing contract from a key department
of the United States government. The contract focuses on supporting
clinical development of a topical dermal treatment for the
prevention of skin cancer. Under terms of the new, multi-year, $1.5
million contract, the company will formulate, manufacture and
supply a topical dermal drug product containing a prespecified
active pharmaceutical ingredient, as well as a matching placebo,
for a planned cancer prevention clinical study. These activities
will include analytical method development, formulation, cGMP
clinical trial material manufacturing, packaging and labeling
services to support the planned clinical trial, which is designed
to evaluate the effects of chemoprevention with the investigational
compound on the recurrence of basal cell carcinoma. This project
showcases Recro’s broad ranging clinical trial services as well as
the company’s unique formulation expertise.
- Existing customer project
expansions. During the fourth quarter, the company
signed multiple development and manufacturing agreements with
existing customers. These include an expanded relationship with
Otsuka. Under the terms of the new master supply and services
agreement, Recro will serve as a commercial manufacturer and
supplier for Otsuka. Recro has already been engaged with Otsuka to
conduct tech transfer work for a branded commercial product which,
when complete, will be produced under the new master supply and
services agreement. Recro is very pleased to expand its work with
Otsuka and the company believes this agreement highlights its
ability to serve as a trusted U.S. supply source for developers of
small molecule therapeutics.Recro was also recently awarded a new
development and manufacturing contract by the National Center for
Advancing Translational Sciences (NCATS) at the National Institutes
of Health (NIH). The new contract falls under an existing NIH
parent contract (N01TR-17-2003), and will focus on the development
of NES-100, a novel nasal spray analgesic. Under terms of the
new contract, the company will support chemistry, manufacturing and
controls (CMC) development of NES-100, a microparticle dosage form
of leu-enkephalin (or LENK) that is prepared by the encapsulation
of LENK in a patent-protected molecular enveloped technology and
delivered via a nasal spray device. In addition to providing early
stage development support, this project will utilize the company’s
sophisticated spray drying capabilities, and Recro is very pleased
to have been selected for this complex process.
Financial Results for the Three Months
Ended December 31, 2021
At December 31, 2021, Recro had cash and cash
equivalents of $25.2 million compared to $23.8 million as of the
end of the prior fiscal year.
Revenues for the quarter ended December 31, 2021
were $22.3 million. This represents a 125% increase compared to
revenues of $9.9 million recorded during the prior year period. The
increase of $12.4 million was primarily the result of increases in
revenue due to the acquisition of IriSys, higher revenues from our
clinical trial materials business as well as higher revenue from
our legacy commercial business due to timing of customer orders in
2020 which resulted in much lower sales in the fourth quarter of
2020.
Cost of sales for the quarter ended December 31,
2021 was $15.7 million compared to $12.5 million for the comparable
period of 2020. The increase of $3.2 million was primarily due to
costs from the San Diego facility due to the acquisition of IriSys
and higher product and clinical material sales offset by increased
production volumes.
Selling, general and administrative expenses for
the fourth quarter were $5.3 million, compared to $4.0 million
recorded in the 2020 period. The increase of $1.3 million was
primarily related to deal and integration costs related to the
acquisition of IriSys and administrative expenses associated with
our San Diego team offset by lower public company costs and
stock-based compensation expense. As a result of our integration
and reorganization, effective October 1, 2021, certain expenses
associated with employees who now support our multi-site
organization structure and operations are classified in selling,
general and administrative expenses. Prior to October 1, 2021,
these employees supported our plant operations and were classified
in cost of sales.
Interest expense was $3.5 million for the three
months ended December 31, 2021, a decrease compared to $4.4 million
for the comparable period of 2020. The decrease of $0.9 million was
primarily due to reduced term loan borrowings under the Credit
Agreement with Athyrium as well as an overall decrease in the rate
of interest on our term loans under the Credit Agreement. This
decrease was partially offset by an increase in interest from the
sellers note which was a component of the IriSys acquisition
purchase price.
For the quarter ended December 31, 2021, the
company recorded a net loss of $2.4 million or $0.04 per diluted
share, as compared to a net loss of $11.7 million or $0.48 per
diluted share, for the comparable period of 2020. EBITDA, as
adjusted* for the period was $3.2 million compared to $0.3 million
in the prior year period.
Financial Results for the Year Ended
December 31, 2021
Revenue for the year ended December 31, 2021 was
$75.4 million, a 13% increase, compared to $66.5 million for the
same period in 2020. The increase of $8.9 million in revenue was
primarily the result increases in revenue due to the acquisition of
IriSys as well as higher revenues from our clinical trial materials
business including revenue from a commercial product tech transfer
project. Despite the discontinuation of two commercial product
lines by our commercial partners announced in the first quarter of
2020, our legacy commercial business has remained relatively flat
in 2021 compared to 2020 as our other commercial products saw
growth in 2021 compared to 2020 rebounding from lower volumes in
2020 due to impacts to the market from COVID-19.
Cost of sales for the year ended December 31,
2021 was $55.6 million, compared to $54.1 million for the same
period in 2020. The cost of sales increase of $1.5 million was
primarily due to costs from the San Diego facility due to the
acquisition of IriSys and is partially offset by lower costs due to
the prior year reduction in force and certain employment incentive
tax credits in 2021.
Selling, general and administrative expenses for
the year ended December 31, 2021 were $18.4 million, compared to
$18.1 million for the same period in 2020. The increase of $0.3
million was primarily related to deal and integration costs related
to the acquisition of IriSys and administrative expenses associated
with the addition of our San Diego team offset by lower public
company costs and stock-based compensation expense. As a result of
our integration and reorganization, effective October 1, 2021,
certain expenses associated with employees who now support our
multi-site organization structure and operations are classified in
selling, general and administrative expenses. Prior to October 1,
2021, these employees supported our plant operations and were
classified in cost of sales.
Interest expense was $15.1 million and $19.2
million during the years ended December 31, 2021 and 2020,
respectively. The decrease of $4.1 million was primarily due to
reduced term loan borrowings under the Credit Agreement with
Athyrium as well as an overall decrease in the rate of interest on
our term loans under the Credit Agreement. This decrease was
partially offset by an increase in interest from the sellers note
which was a component of the IriSys acquisition purchase price.
For the year ended December 31, 2021, Recro
reported a net loss of $11.4 million, or $0.26 per diluted share,
compared to a net loss of $27.5 million, or $1.16 per diluted
share, for the comparable period in 2020. EBITDA, as adjusted* for
the period was $16.6 million compared to $14.0 million in the prior
year period.
*EBITDA, as adjusted is a non-GAAP financial
measure (see reconciliation of non-GAAP financial measures in this
release).
Financial Guidance
For the full year 2022, the company expects
revenue to be approximately $90 to $95 million, net loss to be in
the range of $(13.2) million to $(11.2) million, and EBITDA, as
adjusted* to be in the range of $16 to $18 million. This guidance
takes into consideration existing market forces, contracts, timing
of customer orders, the accuracy of our customers’ product market
estimations, and the company’s current beliefs and estimations with
respect to success and timing related to growing and diversifying
the company’s new business development services revenue. The
company cautions against extrapolating quarterly results to
estimate full year results.
*EBITDA, as adjusted is a non-GAAP financial
measure (see reconciliation of non-GAAP financial measures in this
release).
Non-GAAP Financial Measures
To supplement our financial results determined
by U.S. generally accepted accounting principles (“GAAP”), we have
certain non-GAAP information for our business, including EBITDA, as
adjusted. We believe this non-GAAP financial measure is helpful in
understanding our business as it is useful to investors in allowing
for greater transparency of supplemental information used by
management. This measure is used by investors, as well as
management in assessing our performance. Non-GAAP financial
measures should be considered in addition to, but not as a
substitute for, reported GAAP results. Further, Non-GAAP financial
measures, even if similarly titled, may not be calculated in the
same manner by all companies, and therefore should not be
compared. Please see the section of this press release titled
“Reconciliation of GAAP to Non-GAAP Financial Measures” for a
reconciliation of non-GAAP adjusted EBITDA to its most directly
comparable GAAP measure.
Conference Call and Webcast
Recro management will be hosting a conference
call and webcast today beginning at 4:30 p.m. ET. To access the
conference call, please dial (844) 243-4691 (local) or (225)
283-0379 (international) at least 10 minutes prior to the start
time and refer to conference ID 7549058. A live audio webcast
of the call will be available under "Events" in the Investor
section of the company's website,
https://ir.recropharma.com/events. An archived webcast will be
available on the company's website approximately two hours after
the event and will be available for 30 days.
About Recro
Recro (NASD: REPH) is a bi-coastal contract
development and manufacturing organization (CDMO) with capabilities
spanning pre-Investigational New Drug (IND) development to
commercial manufacturing and packaging for a wide range of
therapeutic dosage forms with a primary focus in the area of small
molecules. With an expertise in solving complex manufacturing
problems, Recro is a leading CDMO providing therapeutic
development, end-to-end regulatory support, clinical and commercial
manufacturing, aseptic fill/finish, lyophilization, packaging and
logistics services to the global pharmaceutical market.
In addition to our experience in handling DEA
controlled substances and developing and manufacturing
modified-release dosage forms, Recro has the expertise to deliver
on our clients’ pharmaceutical development and manufacturing
projects, regardless of complexity level. We do all of this in our
best-in-class facilities, which total 145,000 square feet, in
Gainesville, Georgia and San Diego, California.
For more information about Recro’s CDMO
solutions, visit recrocdmo.com.
Cautionary Statement Regarding Forward
Looking Statements
This press release includes forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements, among other things, relate to the company’s
financial guidance; ability to manage costs and to achieve its
financial goals; to operate under increased leverage and associated
lending covenants; to pay its debt under its credit agreement; to
maintain relationships with CDMO commercial partners and develop
additional commercial partnerships; and the company's expectations
regarding the benefits of the acquisition of IriSys. The words
"anticipate", "believe", "could", "estimate", “upcoming”, "expect",
"intend", "may", "plan", "predict", "project", "will" and similar
terms and phrases may be used to identify forward-looking
statements in this press release. Our operations involve risks and
uncertainties, many of which are outside our control, and any one
of which, or a combination of which, could materially affect our
results of operations and whether the forward-looking statements
ultimately prove to be correct. Factors that could cause the
company’s actual outcomes to differ materially from those expressed
in or underlying these forward-looking statements include, but are
not limited to, the ongoing economic and social consequences of the
COVID-19 pandemic, including any adverse impact on the customer
ordering patterns or inventory rebalancing or disruption in raw
materials or supply chain; demand for the company’s services, which
depends in part on customers’ research and development and the
clinical plans and market success of their products; customers'
changing inventory requirements and manufacturing plans; customers
and prospective customers decisions to move forward with the
company’s manufacturing services; the average profitability, or
mix, of the products the company manufactures; the company’s
ability to enhance existing or introduce new services in a timely
manner; fluctuations in the costs, availability, and suitability of
the components of the products the company manufactures, including
active pharmaceutical ingredients, excipients, purchased components
and raw materials, or the company’s customers facing increasing or
new competition; and risks that the results of the combination of
IriSys's business with the company's business may not be as
anticipated. These forward-looking statements should be considered
together with the risks and uncertainties that may affect our
business and future results presented herein along with those risks
and uncertainties discussed in our filings with the Securities and
Exchange Commission at www.sec.gov. These forward-looking
statements are based on information currently available to us, and
we assume no obligation to update any forward-looking statements
except as required by applicable law.
RECRO PHARMA, INC. AND
SUBSIDIARIES Consolidated Balance Sheets (Unaudited)
(amounts in thousands, except share and per share
data) |
|
December 31,2021 |
|
|
December 31,2020 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
25,217 |
|
|
$ |
23,760 |
|
Accounts receivable, net |
|
|
11,913 |
|
|
|
9,033 |
|
Contract asset |
|
|
8,565 |
|
|
|
7,330 |
|
Inventory |
|
|
8,917 |
|
|
|
11,612 |
|
Prepaid expenses and other current assets |
|
|
2,917 |
|
|
|
2,334 |
|
Total current assets |
|
|
57,529 |
|
|
|
54,069 |
|
Property, plant and equipment, net |
|
|
51,708 |
|
|
|
43,841 |
|
Operating lease asset |
|
|
5,924 |
|
|
|
486 |
|
Intangible assets, net |
|
|
3,833 |
|
|
|
700 |
|
Goodwill |
|
|
41,077 |
|
|
|
4,319 |
|
Other assets |
|
|
246 |
|
|
|
— |
|
Total assets |
|
$ |
160,317 |
|
|
$ |
103,415 |
|
Liabilities and shareholders’ equity
(deficit) |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
2,085 |
|
|
$ |
1,804 |
|
Current portion of debt |
|
|
— |
|
|
|
1,474 |
|
Current portion of related party debt |
|
|
2,039 |
|
|
|
— |
|
Current portion of operating lease liability |
|
|
1,055 |
|
|
|
145 |
|
Accrued expenses and other current liabilities |
|
|
12,556 |
|
|
|
4,380 |
|
Total current liabilities |
|
|
17,735 |
|
|
|
7,803 |
|
Debt, net of current portion |
|
|
92,127 |
|
|
|
108,097 |
|
Related party debt, net of current portion |
|
|
3,369 |
|
|
|
— |
|
Operating lease liability, net of current portion |
|
|
4,932 |
|
|
|
366 |
|
Other liabilities |
|
|
90 |
|
|
|
1,249 |
|
Total liabilities |
|
|
118,253 |
|
|
|
117,515 |
|
Commitments and contingencies |
|
|
|
|
|
|
Shareholders’ equity (deficit): |
|
|
|
|
|
|
Preferred stock, $0.01 par value. 10,000,000 shares authorized,
none issued or outstanding |
|
|
— |
|
|
|
— |
|
Common stock, $0.01 par value. 95,000,000 shares authorized,
46,681,453 and 28,601,358 shares issued and outstanding at
December 31, 2021 and December 31, 2020,
respectively |
|
|
467 |
|
|
|
286 |
|
Additional paid-in capital |
|
|
287,351 |
|
|
|
219,998 |
|
Accumulated deficit |
|
|
(245,754 |
) |
|
|
(234,384 |
) |
Total shareholders’ equity (deficit) |
|
|
42,064 |
|
|
|
(14,100 |
) |
Total liabilities and shareholders’ equity (deficit) |
|
$ |
160,317 |
|
|
$ |
103,415 |
|
|
|
|
|
|
|
|
|
|
RECRO PHARMA, INC. AND
SUBSIDIARIES Consolidated Statements of Operations
(Unaudited)
|
Year ended December 31, |
|
(amounts in thousands, except share and per share
data) |
2021 |
|
|
2020 |
|
|
2019 |
|
Revenue |
$ |
75,360 |
|
|
$ |
66,499 |
|
|
$ |
99,219 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Cost of sales (excluding amortization of intangible assets) |
|
55,537 |
|
|
|
54,134 |
|
|
|
50,981 |
|
Selling, general and administrative |
|
18,374 |
|
|
|
18,124 |
|
|
|
19,909 |
|
Amortization of intangible assets |
|
1,037 |
|
|
|
2,583 |
|
|
|
2,583 |
|
Change in warrant valuation |
|
— |
|
|
|
— |
|
|
|
2,116 |
|
Total operating expenses |
|
74,948 |
|
|
|
74,841 |
|
|
|
75,589 |
|
Operating income (loss) |
|
412 |
|
|
|
(8,342 |
) |
|
|
23,630 |
|
Interest expense |
|
(15,134 |
) |
|
|
(19,159 |
) |
|
|
(19,005 |
) |
Gain on extinguishment of debt |
|
3,352 |
|
|
|
— |
|
|
|
— |
|
(Loss) income from continuing operations |
|
(11,370 |
) |
|
|
(27,501 |
) |
|
|
4,625 |
|
Loss on discontinued operations |
|
— |
|
|
|
— |
|
|
|
(23,255 |
) |
Net loss |
$ |
(11,370 |
) |
|
$ |
(27,501 |
) |
|
$ |
(18,630 |
) |
|
|
|
|
|
|
|
|
|
(Loss) income per share information: |
|
|
|
|
|
|
|
|
Basic: |
|
|
|
|
|
|
|
|
Continuing operations |
$ |
(0.26 |
) |
|
$ |
(1.16 |
) |
|
$ |
0.21 |
|
Discontinued operations |
|
— |
|
|
|
— |
|
|
|
(1.04 |
) |
Total |
$ |
(0.26 |
) |
|
$ |
(1.16 |
) |
|
$ |
(0.83 |
) |
Weighted average shares outstanding |
|
44,117,473 |
|
|
|
23,744,313 |
|
|
|
22,414,194 |
|
Diluted |
|
|
|
|
|
|
|
|
Continuing operations |
$ |
(0.26 |
) |
|
$ |
(1.16 |
) |
|
$ |
0.20 |
|
Discontinued operations |
|
— |
|
|
|
— |
|
|
|
(0.99 |
) |
Total |
$ |
(0.26 |
) |
|
$ |
(1.16 |
) |
|
$ |
(0.79 |
) |
Weighted average shares outstanding |
|
44,117,473 |
|
|
|
23,744,313 |
|
|
|
23,608,862 |
|
|
|
|
|
|
|
|
|
|
|
|
|
RECRO PHARMA, INC. AND
SUBSIDIARIES Reconciliation of GAAP to Non-GAAP Measures
(Unaudited)
To supplement our financial results determined
by U.S. generally accepted accounting principles (“GAAP”), we have
disclosed in the tables below the following non-GAAP information
about EBITDA, as adjusted.
EBITDA, as adjusted, is net income or loss as
determined under GAAP excluding interest, depreciation,
amortization, non-cash stock-based compensation, charges related to
reductions in force and costs related to the acquisition and
integration of IriSys, as well as the impact of Accounting
Standards Update 2014-09 in order to remove the impact of the
timing of revenue recognized from profit-sharing arrangements upon
transfer of control of the product, which more closely aligns
revenue with expected cash receipt.
We believe that non-GAAP financial measures are
helpful in understanding our business as it is useful to investors
in allowing for greater transparency of supplemental information
used by management. EBITDA, as adjusted, is used by investors, as
well as management in assessing our performance. Non-GAAP financial
measures should be considered in addition to, but not as a
substitute for, reported GAAP results. Further, Non-GAAP financial
measures, even if similarly titled, may not be calculated in the
same manner by all companies, and therefore should not be
compared.
Fourth quarter results
|
Three months ended December 31, |
|
(amounts in millions) |
2021 |
|
|
2020 |
|
Net income (loss) (GAAP) |
$ |
(2.4 |
) |
|
$ |
(11.7 |
) |
Interest expense |
|
3.5 |
|
|
|
4.5 |
|
Depreciation |
|
1.7 |
|
|
|
2.3 |
|
Amortization of intangible assets |
|
0.2 |
|
|
|
0.7 |
|
Stock-based compensation |
|
0.1 |
|
|
|
2.0 |
|
Reduction in force (a) |
|
— |
|
|
|
0.1 |
|
Revenue recognition (b) |
|
(0.9 |
) |
|
|
2.4 |
|
Deal and integration costs (c) |
|
1.0 |
|
|
|
— |
|
EBITDA, as adjusted |
$ |
3.2 |
|
|
$ |
0.3 |
|
|
|
|
|
|
|
|
|
Full year results and 2022
guidance
|
Year ended December 31, |
|
(amounts in millions) |
2022 |
|
|
2021 |
|
|
2020 |
|
|
(estimate) |
|
|
|
|
|
|
|
Net loss (GAAP) |
($13.2) - ($11.2) |
|
|
$ |
(11.4 |
) |
|
$ |
(27.5 |
) |
Interest expense |
14.7 |
|
|
|
15.2 |
|
|
|
19.2 |
|
Depreciation |
7.7 |
|
|
|
6.5 |
|
|
|
6.9 |
|
Amortization of intangible assets |
0.9 |
|
|
|
1.0 |
|
|
|
2.6 |
|
Stock-based compensation |
5.0 |
|
|
|
6.5 |
|
|
|
10.1 |
|
Reduction in force (a) |
— |
|
|
|
— |
|
|
|
1.1 |
|
Revenue recognition (b) |
0.7 |
|
|
|
(0.1 |
) |
|
|
1.6 |
|
Deal and integration costs (c) |
0.2 |
|
|
|
2.3 |
|
|
|
— |
|
Gain on extinguishment of debt (d) |
— |
|
|
|
(3.4 |
) |
|
|
— |
|
EBITDA, as adjusted |
$16.0 - 18.0 |
|
|
$ |
16.6 |
|
|
$ |
14.0 |
|
|
|
|
|
|
|
|
|
|
|
|
- In the first half of 2020, two reductions in force were
executed that affected approximately 15% of the work force and were
driven by lower commercial volumes.
- To exclude the impact of Accounting Standards Update 2014-09,
"Revenue Recognition," related to non-cash changes in our contract
asset.
- Costs related to the acquisition and integration of
IriSys.
- In October 2020, the Company submitted a forgiveness
application for its note under the Paycheck Protection Program of
the Coronavirus Aid, Relief and Economic Security Act of 2020. In
June 2021, the note and all accrued interest thereon was forgiven.
Upon receiving the decision, the Company recorded a gain on
extinguishment of debt for the forgiveness of $3,316 of principal
and $36 of accrued interest.
Contacts
Stephanie Diaz (Investors)
Vida Strategic Partners
(415) 675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
(415) 675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Recro
(770) 531-8365
ryan.lake@recroCDMO.com
Recro Pharma (NASDAQ:REPH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Recro Pharma (NASDAQ:REPH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024